ELI-002

Cancer vaccines are gaining momentum across multiple tumor types, with FDA-approved options like BCG, sipuleucel-T, and talimogene laherparepvec demonstrating clinical utility in bladder cancer, prostate cancer, and melanoma respectively.

Elicio Therapeutics received supportive feedback from the FDA regarding the registrational strategy for ELI-002, an investigational cancer vaccine.

Elicio Therapeutics has completed enrollment in its Phase 2 AMPLIFY-7P study, evaluating ELI-002 7P in patients with mutant KRAS-driven pancreatic cancer at high risk of relapse.

Elicio Therapeutics anticipates completing enrollment for the AMPLIFY-7P Phase 2 trial of ELI-002 in Q4 2024, with interim disease-free survival (DFS) analysis expected in H1 2025.

Elicio Therapeutics' ELI-002 demonstrates durable T cell responses and potential DFS benefit in mKRAS-driven solid tumors, as presented at the SITC Annual Meeting.